Immunology Collaboration and Licensing Deals 2018-2026

Description

The definitive benchmark for immunology dealmaking

Immunology partnering spans a broad range of mechanisms of action and chronic disease indications, with deal structures reflecting both innovation in targeted therapies and lifecycle management strategies.

This report provides a comprehensive and structured analysis of 864 immunology collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how immunology deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by stage, asset type, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a mechanism-diverse and highly competitive therapeutic landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within immunology partnerships, particularly in areas driven by differentiated mechanisms and long-term treatment paradigms.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark live transactions
Prepare for negotiations with well-defined market context
Evaluate partnership opportunities and counterparties
Support internal strategy with robust, defensible data
What's included
864 immunology collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, therapy, and technology)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for immunology dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how immunology partnerships are structured, negotiated, and valued.

Product Code: CP2224

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in immunology dealmaking

2.1. Introduction
2.2. Immunology partnering over the years
2.3. Immunology partnering by deal type
2.4. Immunology partnering by industry sector
2.5. Immunology partnering by stage of development
2.6. Immunology partnering by technology type
2.7. Immunology partnering by therapeutic indication

Chapter 3 - Financial deal terms for immunology partnering

3.1. Introduction
3.2. Disclosed financials terms for immunology partnering
3.3. Immunology partnering headline values
3.4. Immunology deal upfront payments
3.5. Immunology deal milestone payments
3.6. Immunology royalty rates

Chapter 4 - Leading immunology deals and dealmakers

4.1. Introduction
4.2. Most active in immunology partnering
4.3. List of most active dealmakers in immunology
4.4. Top immunology deals by value

Chapter 5 - Immunology contract document directory

5.1. Introduction
5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by immunology therapeutic target
Deal directory
Deal directory - Immunology deals by company A-Z
Deal directory - Immunology deals by technology type
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Immunology partnering since 2018
Figure 2: Immunology partnering by deal type since 2018
Figure 3: Immunology partnering by industry sector since 2018
Figure 4: Immunology partnering by stage of development since 2018
Figure 5: Immunology partnering by technology type since 2018
Figure 6: Immunology partnering by indication since 2018
Figure 7: Immunology deals with a headline value
Figure 8: Immunology deals with upfront payment values
Figure 9: Immunology deals with milestone payment
Figure 10: Immunology deals with royalty rates
Figure 11: Active immunology dealmaking activity since 2018
Figure 12: Top immunology deals by value since 2018